Land: Evrópusambandið
Tungumál: enska
Heimild: EMA (European Medicines Agency)
dimethyl fumarate
Teva GmbH
L04AX07
dimethyl fumarate
Immunosuppressants
Multiple Sclerosis, Relapsing-Remitting; Multiple Sclerosis
Dimethyl fumarate Teva is indicated for the treatment of adult and paediatric patients aged 13 years and older with relapsing remitting multiple sclerosis (RRMS).
Authorised
2022-12-12
37 B. PACKAGE LEAFLET Medicinal product no longer authorised 38 PACKAGE LEAFLET: INFORMATION FOR THE PATIENT DIMETHYL FUMARATE TEVA 120 MG GASTRO-RESISTANT HARD CAPSULES DIMETHYL FUMARATE TEVA 240 MG GASTRO-RESISTANT HARD CAPSULES dimethyl fumarate READ ALL OF THIS LEAFLET CAREFULLY BEFORE YOU START TAKING THIS MEDICINE BECAUSE IT CONTAINS IMPORTANT INFORMATION FOR YOU. - Keep this leaflet. You may need to read it again. - If you have any further questions, ask your doctor or pharmacist. - This medicine has been prescribed for you only. Do not pass it on to others. It may harm them, even if their signs of illness are the same as yours. - If you get any side effects, talk to your doctor or pharmacist. This includes any possible side effects not listed in this leaflet. See section 4. WHAT IS IN THIS LEAFLET 1. What Dimethyl fumarate Teva is and what it is used for 2. What you need to know before you take Dimethyl fumarate Teva 3. How to take Dimethyl fumarate Teva 4. Possible side effects 5. How to store Dimethyl fumarate Teva 6. Contents of the pack and other information 1. WHAT DIMETHYL FUMARATE TEVA IS AND WHAT IT IS USED FOR WHAT DIMETHYL FUMARATE TEVA IS Dimethyl fumarate Teva is a medicine that contains the active substance DIMETHYL FUMARATE . WHAT DIMETHYL FUMARATE TEVA IS USED FOR DIMETHYL FUMARATE TEVA IS USED TO TREAT RELAPSING-REMITTING MULTIPLE SCLEROSIS (MS) IN PATIENTS AGED 13 YEARS AND OLDER. MS is a long-term condition that affects the central nervous system (CNS), including the brain and the spinal cord. Relapsing-remitting MS is characterised by repeated attacks (relapses) of nervous system symptoms. Symptoms vary from patient to patient, but typically include walking difficulties, feeling off balance and visual difficulties (e.g. blurred or double vision). These symptoms may disappear completely when the relapse is over, but some problems may remain. HOW DIMETHYL FUMARATE TEVA WORKS Dimethyl fumarate Teva seems to work by stopping the body’s defence system from damaging your brain and spinal co Lestu allt skjalið
1 ANNEX I SUMMARY OF PRODUCT CHARACTERISTICS Medicinal product no longer authorised 2 1. NAME OF THE MEDICINAL PRODUCT Dimethyl fumarate Teva 120 mg gastro-resistant hard capsules Dimethyl fumarate Teva 240 mg gastro-resistant hard capsules 2. QUALITATIVE AND QUANTITATIVE COMPOSITION Dimethyl fumarate Teva 120 mg gastro-resistant hard capsules Each gastro-resistant hard capsule contains 120 _ _ mg dimethyl fumarate. Dimethyl fumarate Teva 240 mg gastro-resistant hard capsules Each gastro-resistant hard capsule contains 240 mg dimethyl fumarate. For the full list of excipients, see section 6.1. 3. PHARMACEUTICAL FORM Gastro-resistant hard capsule (gastro-resistant capsule) Dimethyl fumarate Teva 120 mg gastro-resistant hard capsules Capsules size 0, approximately 21.7 mm, with white opaque body and blue opaque cap. Marking 'D120' printed in black ink on cap and body. Dimethyl fumarate Teva 240 mg gastro-resistant hard capsules Capsules size 0, approximately 21.7 mm, with blue opaque body and blue opaque cap. Marking 'D240' printed in black ink on cap and body. 4. CLINICAL PARTICULARS 4.1 THERAPEUTIC INDICATIONS Dimethyl fumarate Teva is indicated for the treatment of adult and paediatric patients aged 13 years and older with relapsing remitting multiple sclerosis (RRMS). 4.2 POSOLOGY AND METHOD OF ADMINISTRATION Treatment should be initiated under supervision of a physician experienced in the treatment of multiple sclerosis. Posology The starting dose is 120 mg twice a day. After 7 days, the dose should be increased to the recommended maintenance dose of 240 mg twice a day (see section 4.4). If a patient misses a dose, a double dose should not be taken. The patient may take the missed dose only if they leave 4 hours between doses. Otherwise the patient should wait until the next scheduled dose. Temporary dose reduction to 120 mg twice a day may reduce the occurrence of flushing and gastrointestinal adverse reactions. Within 1 month, the recommended maintenance dose of 240 mg Medicinal product no longer authorised Lestu allt skjalið